Galapagos NV (GLPG) Short Interest Down 27.4% in September
Galapagos NV (NASDAQ:GLPG) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 403,300 shares, a decrease of 27.4% from the August 31st total of 555,345 shares. Based on an average daily volume of 105,234 shares, the short-interest ratio is currently 3.8 days.
A number of hedge funds have recently bought and sold shares of GLPG. Federated Investors Inc. PA increased its position in Galapagos NV by 36.8% during the second quarter. Federated Investors Inc. PA now owns 1,364,600 shares of the biotechnology company’s stock valued at $104,419,000 after acquiring an additional 366,800 shares during the last quarter. Renaissance Technologies LLC increased its position in Galapagos NV by 49.5% during the second quarter. Renaissance Technologies LLC now owns 465,300 shares of the biotechnology company’s stock valued at $35,605,000 after acquiring an additional 154,100 shares during the last quarter. Clough Capital Partners L P increased its position in Galapagos NV by 336.1% during the first quarter. Clough Capital Partners L P now owns 74,870 shares of the biotechnology company’s stock valued at $6,453,000 after acquiring an additional 57,700 shares during the last quarter. Wellington Management Group LLP increased its position in Galapagos NV by 9.5% during the first quarter. Wellington Management Group LLP now owns 458,088 shares of the biotechnology company’s stock valued at $39,483,000 after acquiring an additional 39,729 shares during the last quarter. Finally, Dorsey Wright & Associates purchased a new stake in shares of Galapagos NV during the second quarter valued at $1,151,000. Institutional investors and hedge funds own 23.62% of the company’s stock.
A number of brokerages have recently issued reports on GLPG. Zacks Investment Research raised shares of Galapagos NV from a “sell” rating to a “hold” rating in a research note on Wednesday. Royal Bank Of Canada began coverage on shares of Galapagos NV in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $98.00 price objective for the company. Stifel Nicolaus upped their price objective on shares of Galapagos NV from $101.00 to $120.00 and gave the company a “buy” rating in a research note on Friday, September 15th. Morgan Stanley reissued an “overweight” rating and set a $123.00 price target (up previously from $92.00) on shares of Galapagos NV in a research report on Friday, October 6th. Finally, BidaskClub raised shares of Galapagos NV from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $108.14.
Shares of Galapagos NV (NASDAQ:GLPG) traded down 1.69% during midday trading on Friday, reaching $101.55. 44,856 shares of the company’s stock traded hands. The company’s market capitalization is $5.17 billion. Galapagos NV has a one year low of $57.16 and a one year high of $104.12. The company has a 50-day moving average of $101.61 and a 200-day moving average of $101.61.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Marea Informative and is the property of of Marea Informative. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at http://www.mareainformativa.com/galapagos-nv-glpg-short-interest-down-27-4-in-september/116620/.
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Stock Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related stocks with our FREE daily email newsletter.